About SAIGENCI

Bringing the best minds in cancer research under one roof.

The South Australian immunoGENomics Cancer Institute (SAiGENCI) will be the state’s world-class cancer research institute, jointly resourced by the Federal Department of Health, CALHN and the University of Adelaide. This Institute was made possible by $80 million in Commonwealth funding secured with the support of South Australian Senator Stirling Griff

SAiGENCI will allow for coordinated collaboration in the fight to control cancer and explore a cure, by attracting and retaining brilliant biomedical and clinical researchers. The Institute will also collaborate externally, with likeminded centres of excellence across the globe. Delivering world-class and life-changing treatments and outcomes for cancer patients.

SAiGENCI’s objectives include:

  • Forging strong research collaborations
  • Developing and testing new technologies and discoveries
  • Improving treatment and care options for people living with cancer
  • Training South Australian clinicians
  • Commercialising new discoveries

SAiGENCI’s plans

The plans for the South Australian immunoGENomics Cancer Institute are ambitious. The aim is to provide a focal point for cancer research in the South Australian Biomedical Precinct and through this, enable South Australian participation in the growing Australian network of cancer institutes, and national and international clinical trials partnerships.

We aim to create an environment that will attract talent to South Australia, but also see this as becoming the South Australian node of the national cancer research effort.

Collaboration and institutional partnership will be fundamental to our success and will underpin the impact we aim to have on the generation of new knowledge, and its application to the benefit of patients.

Specifically, this will involve:

  1. Creating an intellectual environment in SAiGENCI that is a magnet for the attraction and retention of clinical academic and cancer research talent, establishing an aggressive national and international recruitment program that builds research, translation and clinical capability in cancer immunotherapy and cell therapy in South Australia.
  2. Establishing platforms and technologies to expand genomic and related (eg epigenomic, transcriptomic, metabolomic) profiling of tumours which will facilitate research, clinical trials, and ultimately, enable precision oncology.
  3. Integrating South Australian cancer research, clinical trials, care and education with national networks and programs.
  4. Partnering with the Central Adelaide Local Health Network to facilitate the implementation of national cancer care pathways and policies and enhancing clinical trials for South Australian patients.
  5. Contributing to the development of contemporary and cutting-edge training programs for clinician scientists, research scientists and the health and medical research workforce.
  6. Collaborating with partners in the Adelaide Biomedical Precinct to create a world-class clinical trials infrastructure that will attract national and international industry-sponsored and investigator-led clinical trials.
  7. Working with the wider University and Central Adelaide Local Health Network to build relationships within the philanthropic sector that will help to diversify and strengthen the institute’s revenues into the long-term future.